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Abstract	
Current	medical	practice	artificially	dichotomises	a	diagnosis	of	 fatty	 liver	disease	 into	one	of	
two	 common	 forms:	 Alcoholic	 Liver	 Disease	 (ALD)	 and	 Non-Alcoholic	 Fatty	 Liver	 Disease	
(NAFLD).	 Together,	 these	make	up	 the	majority	 of	 chronic	 liver	 disease	worldwide.	 In	 recent	
years,	there	has	been	a	dramatic	increase	in	the	prevalence	of	obesity	and	metabolic	syndrome	
risk-factors	 within	 the	 general	 population	 and	 so	 these	 factors	 now	 coexist	 with	 alcohol	
consumption	in	a	substantial	proportion	of	the	population.	Each	exposure	sensitises	the	liver	to	
the	 injurious	 effects	 of	 the	 other;	 an	 interaction	 that	 drives	 and	 potentially	 accelerates	 the	
genesis	of	 liver	disease.	We	review	the	epidemiological	evidence	and	scientific	 literature	 that	
considers	how	alcohol	consumption	 interacts	with	components	of	the	metabolic	syndrome	to	
exert	additive	and	synergistic	effects	on	the	development	and	progression	of	liver	disease	and	
discuss	how	these	interactions	may	be	addressed	in	clinical	practice.		
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1. Introduction	
Current	medical	practice	tends	to	dichotomise	a	diagnosis	of	fatty	liver	disease	into	one	of	two	
common	 forms,	Alcoholic	 Liver	Disease	 (ALD)	 and	Non-Alcoholic	 Fatty	 Liver	Disease	 (NAFLD),	
based	on	a	widely-adopted	threshold	 for	alcohol	consumption	set	at	20g/day	for	women	and	
30g/day	 for	men	 [1,	2].	 Together,	ALD	and	NAFLD	make	up	 the	vast	majority	of	 chronic	 liver	
disease	worldwide	and	are	consuming	an	 increasing	proportion	of	healthcare	resources.	Both	
conditions	 share	 many	 pathophysiological	 processes	 and	 have	 similar	 histological	 features:	
steatosis	(hepatic	triglyceride	content	[HTGC]	>	5%),	steatohepatitis,	fibrosis	and	cirrhosis	[3].		
	
In	 terms	 of	 aetiology,	 the	 relationship	 between	 sustained	 high	 alcohol	 consumption	 and	
progressive	 liver	 disease	 is	 well	 established.	 The	 risk	 of	 liver	 disease	 increases	 as	 alcohol	
consumption	rises	beyond	~30g/day:	7.1-fold	relative	risk	at	50g/day,	rising	to	a	26-fold	relative	
risk	at	100g/day	[4,	5].	Similarly,	NAFLD	is	driven	by	the	presence	of	sustained	dietary	calorific	
excess,	being	most	commonly	found	in	patients	that	exhibit	multiple	features	of	the	metabolic	
syndrome	 (central	obesity,	 type	2	diabetes	mellitus	 [T2DM],	dyslipidaemia	and	hypertension)	
[6].		
	
Both	ALD	and	NAFLD	are	characterized	by	substantial	interpatient	variation	in	disease	severity,	
risk	 of	 progression	 to	 cirrhosis	 and	 long-term	 outcomes	 such	 as	 hepatic	 decompensation	 or	
hepatocellular	 carcinoma	 (HCC).	 Over	 the	 last	 50-years,	 lifestyles	 have	 become	 increasingly	
sedentary	and	dietary	patterns	have	changed,	dramatically	increasing	the	prevalence	of	obesity	
and	metabolic	 syndrome	risk-factors	within	 the	general	population.	Given	 that	approximately	
70%	of	the	adults	in	the	WHO	European	Region	drink	alcohol	[7],	with	a	mean	consumption	of	
10.7	 litres	 of	 pure	 ethanol	 per	 year	 [8],	 metabolic	 risk	 factors	 and	 some	 level	 of	 alcohol	
consumption	 now	 coexist	 in	 a	 substantial	 proportion	 of	 the	 population	 with	 each	 exposure	
potentially	sensitizing	the	 liver	 to	the	 injurious	effects	of	 the	other.	Much	emphasis	has	been	
placed	on	exploring	how	genetic	factors	modify	disease	progression	in	NAFLD	and	ALD	[3]	but	it	
is	 also	 important	 to	 consider	 how	 the	 combined	 environmental	 challenges	 of	 alcohol	
consumption	 and	 calorific	 excess/metabolic	 risk	 may	 interact	 to	 modify	 progression	 of	 liver	
disease.	 Such	 interactions	 are	 clearly	 relevant	 at	 excessive	 levels	 of	 alcohol	 consumption	but	
perhaps	even	more	so	in	patients	where	alcohol	consumption	is	less	extreme.	For	the	purpose	
of	 this	article,	a	 search	of	 the	PubMed	MEDLINE	database	was	conducted,	and	 the	 reference	
lists	in	review	articles	and	original	research	were	examined.	
Boyle	et	al	 	 Page	4	of	38	
	
2. Epidemiology:	Frequency	of	Obesity	and	Alcohol	as	cofactors	for	Liver	Disease	
The	burden	of	ALD	is	hard	to	accurately	quantify	with	wide	international	variations	and	trends	
in	the	reported	prevalence	and	 impact	of	ALD.	The	prevalence	of	ALD	 in	the	US	population	 is	
currently	estimated	to	be	2.0%–2.5%	[9].	The	National	Health	and	Nutrition	Examination	Survey	
(NHANES)	 reports	 that	ALD	prevalence	 increased	 from	1.38%	during	 the	period	 from	1988	 to	
1994	to	2.21%	during	the	period	from	1999	to	2004,	but	then	remained	stable,	at	2.05%,	during	
the	period	 from	2005	to	2008	[10].	 In	Europe,	some	countries	have	reported	a	decline	 in	 the	
burden	of	ALD,	while	 others	 have	 reported	 a	 recent	 increase	 in	mortality	 from	ALD	 cirrhosis	
[11].	 However,	 it	 is	 clear	 that	 excessive	 alcohol	 consumption	 is	 a	 significant	 public	 health	
challenge,	with	an	attributable	burden	of	premature	mortality	and	ill-health	which	is	highest	in	
Europe	and	North	America	and	disproportionately	affects	younger	people	[12].	
	
Obesity	 rates	have	been	 increasing	 in	all	 territories	worldwide	but	particularly	 in	middle-	and	
high-income	countries.	The	2014	WHO	Report	on	Non-Communicable	Diseases	found	that	39%	
of	 adults	 (38%	of	males	 and	 40%	of	 females)	worldwide	were	overweight	with	 a	 near	 2-fold	
increase	 in	the	prevalence	of	obesity	between	1980	and	2014	[13].	The	highest	prevalence	of	
overweight	and	obesity	was	seen	in	the	Americas	where	61%	were	overweight	or	obese	(27%	
obese)	and	lowest	in	South-East	Asia	(22%	overweight,	5%	obese).	In	Europe,	over	half	the	adult	
population	is	overweight	and	20-25%	of	the	population	is	obese.	Similarly,	8-10%	of	the	adult	
population	have	T2DM	[13].	 In	 light	of	 this	 it	 is	perhaps	unsurprising	that	 there	 is	also	a	high	
prevalence	of	NAFLD	worldwide,	with	approximately	25%	of	 the	adult	population	affected	by	
NAFLD	 [14,	 15].	 Even	 if	 one	 adopts	 a	 conservative	 approach	 and	 assumes	 that	 up	 to	 1	 in	 10	
cases	may	be	undetected	excessive	drinkers	that	have	been	being	misclassified	as	NAFLD,	it	 is	
apparent	that	a	substantial	burden	of	NAFLD	exists	within	the	general	population	[16].		
	
The	association	between	alcohol	consumption	and	obesity	is	complex.	Numerous	studies	have	
linked	moderate	to	heavy	alcohol	use	with	weight	gain	and	obesity	[17-20].	In	a	recent	review	
of	 alcohol	 consumption	 and	 obesity,	 it	 was	 concluded	 that	 alcohol	 intake	 may	 confer	 an	
increased	 risk	 of	 obesity	 in	 some	 individuals.	 Available	 studies	 reviewed	 were	 however	
conflicting,	 variously	 finding	 either	 no	 association,	 a	 positive,	 or	 a	 negative	 association	 with	
binge/heavy	 drinking,	 frequency	 and	 intensity	 [21].	 Worryingly,	 in	 a	 recent	 study	 in	 young	
adults,	regular	heavy	alcohol	consumption	was	associated	with	weight	gain	[22].	Data	from	the	
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German	Study	of	Health	in	Pomerania	(SHIP)	established	the	prevalence	of	people	meeting	the	
criteria	for	both	NAFLD	and	ALD	[23].	In	the	adult	male	population	of	Northeast	Germany	17.5%	
of	 subjects	 exhibit	 risk	 criteria	 for	 both	 NAFLD	 and	 ALD	 (i.e.	 obese	 and	 consuming	 >30	 g	
alcohol/day)	 [23].	 Similar	 findings	 have	 been	 reported	 in	 Finnish	 adults	 [24],	 where	 patients	
with	ALD	were	as	 likely	to	be	obese	as	patients	 identified	as	having	“non-alcoholic”	fatty	 liver	
disease.	 Indeed,	 the	 same	 study	 reported	 that	 the	metabolic	 syndrome	was	more	 frequently	
present	in	ALD	than	NAFLD	patients.	These	data	highlight	the	degree	of	overlap	that	exists	and	
that	coexisting	high	alcohol	consumption	and	overweight/obesity	are	 frequently	encountered	
in	day-to-day	clinical	practice.		
	
Further	 emphasising	 the	 relationship	 between	 alcohol	 and	 obesity	 as	 co-factors	 for	 liver	
disease,	 it	 has	 been	 shown	 that	 patients	 often	 develop	 obesity	 after	 drinking	 cessation.	 In	 a	
Danish	 cohort	 of	 6,514	 individuals,	 a	 variant	 in	 FGF21	 was	 associated	 with	 increased	
consumption	 of	 candy	 and	 increased	 alcohol	 intake,	 suggesting	 that	 the	 FGF21	 hormone	
secreted	by	the	liver	may	influence	nutrient	choices	[25]		
	
3. Pathogenesis	of	ALD	and	NAFLD	
A	 full	 discussion	 of	 the	 pathogenesis	 of	 NAFLD	 and	 ALD	 is	 outside	 the	 scope	 of	 the	 current	
article.	Both	ALD	and	NAFLD	unarguably	exhibit	disease	specific	components	[26,	27].	However,	
given	their	striking	histological	similarities,	it	is	not	surprising	that	there	are	many	mechanisms	
common	 to	 the	 development	 and	 progression	 of	 both	 (Figure	 1)	 [26,	 28].	 Numerous	 studies	
demonstrate	 that	 the	 transition	 from	 steatosis	 to	 steatohepatitis	 in	 both	 NAFLD	 and	 ALD	 is	
characterised	by	both	mitochondrial	dysfunction	and	increasing	hepatocellular	oxidative	stress	
[29-31].	 Other	 well	 validated	 contributory	 factors	 include	 endotoxaemia	 derived	 from	 gram-
negative	bacteria	amongst	the	gut	 flora	that	enter	the	portal	circulation	due	to	 increased	gut	
permeability	and	subsequently	provoke	inflammatory	processes	in	both	NAFLD	and	ALD	[26,	32,	
33].	 In	addition,	there	 is	also	some	evidence	to	suggest	that	the	bacterial	 flora	within	the	gut	
may	contribute	to	the	pathogenesis	of	NAFLD	through	endogenous	alcohol	production.	Murine	
studies	 have	demonstrated	 alcohol	may	be	produced	by	 the	 gut	 flora,	with	 greater	 amounts	
being	 produced	 in	 obese	 vs.	 lean	 animals[34].	 Supporting	 this	 contributory	 hypothesis,	
hepatocytes	 from	 young	 patients	 with	 NASH	 have	 been	 found	 to	 express	 genes	 encoding	
alcohol	degradation	pathways	despite	patients	abstaining	from	alcohol	[35].	Furthermore,	in	a	
recent	animal	study	[36],	researchers	attempted	to	demonstrate	that	NAFLD	is,	at	least	in	part,	
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the	product	of	endogenous	alcohol	production	[37-39]	and	that	potentially	hepatotoxic	 levels	
of	alcohol	 could	be	produced	and	upregulation	of	 genes	 in	 relevant	metabolic	pathways	 [40-
43].	 It	 is	 unlikely	 that	 endogenous	 alcohol	 production	alone	 is	 sufficient	 to	 cause	NAFLD	and	
further	 validation	 of	 these	 findings	 in	 humans	 is	 clearly	 needed	 but	 the	 endogenous	 alcohol	
hypothesis	could	open	new	avenues	for	the	treatment	and	prevention	of	NAFLD.		
	
3.1. Genetics	in	NAFLD	and	ALD	
Further	evidence	for	a	shared	pathophysiology	and	the	central	role	of	lipid	metabolism	in	both	
conditions	may	 be	 derived	 from	 genetic	 studies,	which	 have	 demonstrated	 that	 the	 severity	
and	 progression	 of	 both	 NAFLD	 and	 ALD	 are	 influenced	 by	 a	 number	 of	 the	 same	 genetic	
variants,	 recently	 reviewed	 [3].	 These	 include	 a	 common	 non-synonymous	 variant	 (rs738409	
c.444	C>G	p.I148M)	in	the	patatin-like	phospholipase	domain-containing	3	(PNPLA3)	gene	that	
encodes	 adiponutrin,	 a	 protein	 involved	 in	 lipid	metabolism	 [44],	 which	 has	 been	 shown	 to	
influence	severity	of	steatosis,	steatohepatitis	and	fibrosis	and	HCC	risk	 in	NAFLD	[45-47]	and	
ALD	[48-51].	Similarly,	a	variant	in	the	transmembrane	6	superfamily	member	2	(TM6SF2)	gene	
(rs5854296	c.449	C>T,	p.E167K)	is	associated	with	increased	severity	of	 liver	disease	in	NAFLD	
[52,	53]	and	ALD	[48]	but	is	protective	against	dyslipidaemia	and	cardiovascular	disease	[54-56].	
Most	 recently,	 a	 variant	 (rs641738)	 in	 the	 membrane	 bound	 O-acyltransferase	 domain	
containing	7-	transmembrane	channel-like	4	(MBOAT7)	gene	has	also	been	shown	to	influence	
disease	progression	in	both	conditions	[3,	48].	
	
3.2. Environmental	Factors	influencing	the	development	and	progression	of	NAFLD	and	ALD	
A	 diagnosis	 of	 NAFLD	 implies	 that	 an	 individual	 has	 evidence	 of	 hepatic	 steatosis	
(biopsy/radiology)	and	that	other	causes	of	fatty	liver	disease	have	been	excluded,	in	particular	
excessive	 alcohol	 consumption.	 However,	 what	 precise	 threshold	 defines	 significant	 alcohol	
consumption	for	discriminating	NAFLD	and	ALD	remains	unclear.	Furthermore,	it	has	also	been	
observed	 that	 in	 addition	 to	 quantity;	 alcoholic	 beverage	 type,	 drinking	 patterns,	 lifestyle	
patterns	 and	 types	 of	 dietary	 fats	 are	 significant	 in	 metabolic	 liver	 disease,	 adding	 further	
complexity	to	study	interpretation.	 
 
3.2.1	Quantity	and	Pattern	of	Alcohol	Consumption	&	Disease	Risk	
The	 alcohol	 consumption	 threshold	 for	 hepatotoxicity	 is	 complicated	 and	 dependent	 on	 a	
variety	 of	 modifiers	 (for	 example,	 gender,	 genetic	 factors	 and	 ethnicity)	 [57].	 It	 is	 generally	
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accepted	that	daily	alcohol	consumption	below	two	drinks	 in	men	and	one	drink	 in	women	is	
unlikely	to	cause	hepatic	steatosis	[58,	59].	The	safe	levels	of	alcohol	consumption	proposed	by	
the	European	Association	for	the	Study	of	the	Liver	(EASL)	and	the	American	Association	for	the	
Study	of	the	Liver	(AASLD)	are	30g/day	and	20g/day	of	alcohol	in	men	and	women	respectively	
[57,	60]	whilst	the	Asian	Pacific	for	the	Study	of	the	Liver	(APASL)	adopts	a	more	conservative	
threshold	of	<20g/day	in	men	and	10g/day	in	women	[61].	It	is	also	apparent	that	the	marked	
differences	between	a	linear	relationship	and	a	“J-shaped”	curve	with	regard	to	risk/benefit	of	
alcohol	consumption	may	harbour	problems	when	disseminating	clear	public	health	messages.	
Indeed,	it	has	been	advised	that	the	public	should	focus	on	the	nadir	of	the	J-shaped	curve	for	
making	 decisions	 about	 drinking.	 Instead,	 many	 moderate	 drinkers	 are	 inclined	 to	 view	 the	
point	on	the	curve	where	the	risk	of	adverse	health	outcomes	exceeds	that	of	abstainers	and	
these	data	do	not	consider	the	synergistic	effects	of	alcohol	and	obesity.	[62].		
	
In	addition	to	the	quantity,	the	pattern	of	alcohol	use	may	be	relevant	in	assessing	the	level	of	
harm.	 The	 number	 of	 days	 per	 week	 on	 which	 alcohol	 is	 consumed,	 the	 typical	 number	 of	
drinks	per	day,	and	evaluation	for	the	presence	of	episodic	heavy	drinking	should	be	performed	
to	characterize	the	moderate	alcohol	user.	For	example,	in	a	recent	Danish	study,	the	amount	
of	alcohol	consumed	per	session	has	been	proposed	to	be	more	important	in	relation	to	risk	of	
developing	T2DM	than	drinking	frequency	[63].	However,	previous	studies	have	reported	that	
binge	drinking	increases	the	risk	of	T2DM	in	men,	but	not	women	[63-66].	Regarding	drinking	
patterns,	the	CAS	study	found	the	“five/four”	measure	of	binge	drinking	to	be	associated	with	a	
substantially	 greater	 risk	 of	 alcohol-related	 health	 and	 social	 problems	 [67].	 However,	 an	
additional	 study	examining	 liver	disease	 in	heavy	drinkers	 that	did/did	not	exhibit	 features	of	
alcohol	 withdrawal	 demonstrated	 a	 negative	 association	 of	 alcohol	 withdrawal	 and	 liver	
cirrhosis,	 an	 effect	 that	 persisted	 even	 after	 adjustment	 for	 gender,	 duration	 and	 pattern	 of	
alcohol	consumption	[68]	
	
3.2.2. Dietary	Constituents	&	Disease	Risk	
Epidemiological	and	experimental	studies	indicate	that	both	quantity	and	the	type	of	dietary	fat	
can	 influences	pathogenesis	 of	ALD	 [69,	 70]	 and	NAFLD	 [71,	 72].	 Saturated	 FFA	 causes	more	
apoptosis	than	unsaturated	fats	in	vitro.	Quality	of	carbohydrates	also	affects	hepatic	steatosis,	
inflammation	and	fibrosis	in	animal	models	[73,	74].		
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A	 cross-sectional	Danish	 study	 reported	 that	 people	who	buy	wine	 tended	 to	 also	 buy	more	
“healthy”	 food	 items	 than	 those	 that	 purchased	 beer	 (i.e.	 wine	 buyers	 favoured	
fruit/vegetables,	olives	and	 low-fat	products;	beer	buyers	 favoured	ready	meals,	 sugar,	chips,	
butter,	sausages	and	soft	drinks)	[75].	These	findings	are	supported	by	other	studies	from	the	
United	States	and	Europe	link	purchase	of	wine	with	fruit,	vegetables,	fish	and	consumption	of	
less	 saturated	 fat	 [76-78].	 Some	 reports	 also	 suggest	 that	 proportionately	 greater	 red	 wine	
consumption	may	reduce	the	relative	risk	of	cirrhosis	[79].	This	requires	independent	validation	
however	 is	 perhaps	 related	 to	 resveratrol,	 a	 polyphenol	 found	 in	 grapes	 [80,	 81].	 Several	
studies	have	 suggested	 that	hop	 ingredients,	 related	 to	beer	making	may	 contain	 substances	
that	 protect	 from	 liver	 damage	 [82]	 and	 may	 also	 positively	 impact	 components	 of	 the	
metabolic	 syndrome	 such	 as	 IR	 and	 body	 weight	 [83].	 However,	 a	 study	 by	 Pelletier	 et	 al	
reported	that	wine	consumption	is	not	associated	with	a	decrease	in	alcoholic	cirrhosis	in	heavy	
drinkers	 [84].	 Extending	 this	 to	 T2DM,	 regarding	 beverage	 type,	 a	 recent	 Danish	 analysis	
suggests	 a	 lower	 risk	 of	 diabetes	 associated	 with	 a	 moderate	 to	 high	 intake	 of	 wine	 and,	
among	women,	a	higher	risk	of	diabetes	associated	with	a	high	intake	of	spirits	[85].		
	
	
3.3. Experimental	(animal)	Models	analysing	the	pathological	effect	of	alcohol	on	
Hepatic	Steatosis	development	and	fibrosis	progression	
Animal	studies	have	been	invaluable;	increasing	our	understanding	of	the	combined	effects	of	
alcohol	 and	 obesity	 on	 hepatic	 steatosis	 and	 fibrosis	 progression.	 A	 consistent	 observation	
during	 the	development	of	 rodent	models	of	ethanol	 induced	 liver	 injury	 in	animals	was	 that	
isolcaloric	 substitution	 of	 ethanol	 for	 dietary	 fat	 did	 not	 produce	 hepatic	 steatosis.	
Furthermore,	 rats	 fed	 an	 ethanol	 containing	 diet	 exhibited	 less	 overall	 weight	 gain	 than	
controls.	 Therefore,	 a	 35%	 fat,	 alcohol-containing	 diet	 comparable	 to	 the	 original	 "Lieber-
DeCarli	 formula"	 (1965)	 has	 been	 widely	 adopted.	 This	 in	 effect	 means	 that	 many	 rodent	
studies	into	ALD	models	are	in	fact	already	dietary	models	of	combined	ALD	and	NAFLD.		[86-
89]	 In	 vivo	 studies	 have	 shown	 that	 consumption	 of	 such	 a	 high	 fat	 (HFD)/high	 alcohol	 diet,	
promotes	 an	 accelerated	 progression	 of	 hepatic	 steatosis,	 inflammation	 and	 fibrosis.	 The	
available	data	suggests	that	moderate	alcohol	intake	augments	inflammation	and	apoptosis	in	
murine	models	with	underlying	NASH.	Overall,	 from	animal	 studies	we	can	conclude	 that	 the	
effect	of	ethanol	consumption	on	NAFLD,	and	its	association	with	obesity	are	complex,	difficult	
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to	 measure	 and	 largely	 deleterious.	 Selected	 animal	 experiments	 that	 investigate	 the	
interaction	between	alcohol	and	obesity	in	liver	injury	are	summarised	in	Table	1.		
	
An	interesting	recent	study	by	Duly	et	al	attempted	to	recapitulate	the	frequently	encountered	
human	 pattern	 of	 background	 high	 fat	 diet	 (HFD)	 consumption	 combined	 with	 intermittent	
alcohol	 ‘binge’	drinking	 in	mice	 [90].	 This	produced	more	 severe	histological	 liver	 injury	 than	
either	 HFD	 or	 alcohol	 consumption	 did	 alone	 [90].	 They	 showed	 that	 alcohol	 and	 HFD	
synergistically	increased	histological	steatosis,	 inflammation	and	promoted	a	molecular	profile	
consistent	with	active	fibrogenesis.	Beyond	the	effects	of	HFD	alone,	alcohol	altered	the	pattern	
of	 histological	 steatosis:	 increasing	 micro-	 and	 macro-vesicular	 lipid	 deposits,	 as	 well	 as	 a	
greater	 Kupffer	 cell	 inflammatory	 infiltrate	 and	 more	 fibrogenic	 HSCs.	 These	 changes	 being	
accompanied	by	upregulation	of	SREBP-1	and	TGF-β	[90].	However,	not	all	in	vivo	studies	have	
supported	 these	 findings.	 Leptin	deficient	ob/ob	mice	develop	obesity,	 insulin	 resistance	 and	
NAFLD	 [91].	 Kanuri	 at	 al	 reported	 that	moderate	 alcohol	 intake	 ameliorated	NAFLD	 in	ob/ob	
mice	 and	 attributed	 this	 apparent	 protective	 effect	 to	 the	 induction	 of	 SIRT1-/adiponectin-
signalling	 in	 visceral	 adipose	 tissue	 that	 in	 turn	 modulated	 hepatic	 adiponectin/AKT/PAI-1	
signalling	 [92,	 93].	 However	 of	 note,	 the	 lack	 of	 leptin	 in	 this	 model	 is	 not	 consistent	 with	
human	NAFLD	phenotype	and	leads	to	a	number	of	other	physiological	changes	that	do	not	well	
recapitulate	human	NAFLD	[91].		
	
To	translate	the	results	into	clinical	decision	making,	there	is	a	need	to	establish	the	potential	
cumulative	 effects	 of	 ethanol	 on	 the	 modulation	 of	 factors	 involved	 in	 the	 pathogenesis	 of	
NAFLD;	 these	 include	 the	 inflammasome,	 gut	 microbiota	 and	 intestinal	 permeability,	 and	
obesity-related	carcinogenesis	[94].		
	
4. Natural	History/Progression	of	Liver	Disease	in	the	setting	of	alcohol	and	obesity	
Both	ALD	and	NAFLD	are	characterized	by	substantial	interpatient	variation	in	disease	severity	
and	risk	of	progression	to	cirrhosis	[5,	95].	We	reviewed	the	published	literature	relating	to	the	
combined	effects	of	 alcohol	 and	 increased	adiposity/obesity	 in	 liver	disease.	 It	 is	 noteworthy	
that	 the	epidemiological	 literature	 falls	 into	 two	seemingly	diametrically	opposed	groups:	 the	
first	reports	patients	that	are	primarily	diagnosed	with	NAFLD	but	who	also	consume	moderate	
levels	 of	 alcohol	 are	 at	 increased	 risk	 of	 developing	 more	 severe	 liver	 disease;	 the	 second	
suggests	 that	 there	 may	 be	 a	 beneficial	 effect	 derived	 from	 light/moderate	 drinking.	
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Unfortunately,	 to	 date,	 the	 highest	 quality	 data	 on	 the	 relationship	 between	 alcohol	
consumption	and	clinical	outcomes	in	patients	with	NAFLD	are	derived	only	from	observational	
studies.		
	
4.2. Bidirectional	Impact	of	Alcohol	and	Metabolic	Syndrome	as	co-factors	for	Liver	
Disease	
4.2.2. The	effects	of	Alcohol	on	Metabolic	Syndrome	related	liver	disease	
Several	 epidemiological	 studies	 support	 the	 view	 that	 there	 is	 a	 strong	 causal	 relationship	
between	 consumption	 of	 a	 diet	 high	 in	 fat	 (and/or	 presence	 of	 T2DM),	 the	 consumption	 of	
alcohol	and	progressive	 liver	disease.	A	summary	of	 these	studies	 is	provided	 in	Table	2.	The	
Dionysos	 study	 in	 Northern	 Italy	 was	 one	 of	 the	 first	 epidemiological	 studies	 to	 show	 that	
hepatic	steatosis	prevalence	was	increased	to	46%	in	subjects	with	an	alcohol	intake	>60g/day,	
and	to	76%	in	the	obese	whereas	steatosis	was	only	found	in	16%	of	lean	controls	[96].	Similar	
additive/synergistic	effects	are	observed	in	the	case	of	hepatocellular	injury	and	inflammation,	
hepatic	fibrosis	and	the	development	of	cirrhosis	[97-102].	In	addition,	the	presence	of	NAFLD	
potentially	 makes	 the	 liver	 more	 sensitive	 to	 other	 injurious	 processes	 such	 as	 alcohol	
consumption.	In	the	UK	prospective	Million	Women	Cohort	study	(1,230,662	women;	mean	age	
56;	6.2-years	of	 follow-up),	 the	 relative	 risk	of	 cirrhosis	 in	 individuals	with	BMI	>30	and	>150	
g/week	alcohol	use	was	6.53,	and	in	individuals	with	normal	BMI	and	>150	g/week	alcohol	use	
the	relative	risk	was	3.44	compared	with	 individuals	with	normal	BMI	and	<70g/week	alcohol	
use	 [103].	 In	 a	 prospective	 evaluation	 in	 9,559	men	 in	 Scotland,	 there	 was	 a	 supra-additive	
between	 alcohol	 consumption	 and	BMI	on	 liver	 disease	morbidity	 and	mortality.	Obese	men	
who	consumed	more	than	120g	of	alcohol	per	week	had	a	relative	rate	of	liver	disease	mortality	
that	was	19	times	greater	than	normal	or	underweight	individuals	who	did	not	consume	alcohol	
[104].	This	equated	to	a	5.58-fold	relative	excess	risk	due	to	the	interaction	between	BMI	and	
alcohol	consumption	[104].	In	a	Finnish	population-based	health	study,	out	of	6,000	individuals,	
84	patients	developed	advanced	liver	disease,	weekly	binge	drinking,	in	combination	with	MetS,	
produced	a	super-additive	increase	in	the	risk	of	decompensated	liver	disease	[105]		
	
In	 contrast,	 other	 epidemiologic	 studies	 from	 Europe,	 USA	 and	 Japan	 have	 suggested	 that	
moderate	 alcohol	 consumption	 may	 ameliorate	 hepatic	 steatosis	 consequent	 to	 an	
improvement	 in	 peripheral	 insulin	 resistance	 [106].	 The	 epidemiological	 studies	 discussed	
below	demonstrate	a	“J-shaped’	relationship	between	degree	of	alcohol	consumption	and	total	
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mortality,	with	reduced	risk	(largely	attributable	to	less	cardiovascular	disease)	for	light	drinkers	
and	increased	risk	for	those	taking	more	than	3-drinks/day.	Infrequent	drinkers	have	risk	similar	
to	 that	 of	 lifelong	 abstainers,	 while	 former	 drinkers	 are	 at	 increased	 risk	 [107].	 Quantitative	
evidence	 from	 nine	 cross-sectional	 studies	 on	 NAFLD	 implied	 beneficial	 effects	 of	 moderate	
alcohol	consumption	(MAC)	defined	as	less	than	40g/day	on	degree	of	hepatic	steatosis.	MAC	
reduced	the	risk	of	having	NAFLD	by	31%	in	a	pooled	sample	of	43,175	individuals	(30,791	non-
drinkers	and	12,384	modest	drinkers)	[108].	MAC	showed	a	protective	effect	of	50%	on	the	risk	
of	 developing	 NASH	 in	 data	 from	 822	 patients	 (550	 non-drinkers	 and	 272	 modest	
drinkers)[108].	 Further	 evidence	 was	 obtained	 from	 a	 longitudinal	 study	 from	 Japan	 (5437	
individuals	 with	 10	 years’	 follow-up).	 The	 calculated	 adjusted	 hazard	 risk	 of	 MAC	 for	 the	
development	of	NAFLD	was	0.69	when	compared	with	non-drinkers	 [109].	Table	3	 shows	the	
studies	supporting	the	beneficial	effects	of	moderate	alcohol	consumption	on	hepatic	steatosis	
development	in	the	setting	of	metabolic	syndrome.		
	
In	 addition	 to	 these	 widely	 cited	 epidemiological	 studies,	 a	 number	 of	 smaller	 studies	 have	
examined	 the	 effect	 of	 alcohol	 drinking	 on	 the	 underlying	 hepatic	 histopathology	 in	 subjects	
with	a	 firm	diagnosis	of	NAFLD.	Table	4	 provides	a	 summary	of	 these	 studies.	 Examining	 the	
effect	 of	 alcohol	 as	 a	 co-factor	 for	 fibrosis	 is	 solely	 a	 histological	 diagnosis	 and	 thus	we	 are	
limited	 in	the	amount	of	studies	available	 for	review	and	the	size	of	 the	cohorts	studied.	The	
study	by	Ekstedt	et	al	reported	a	more	rapid	rate	of	fibrosis	progression	in	patients	with	NAFLD	
that	drank	moderate	amounts	of	alcohol.	Among	71	patients	with	paired-liver	biopsies,	binge	
drinking	 and	 insulin	 resistance	were	 independent	 factors	 associated	with	 fibrosis	 progression	
over	a	mean	13.8-year	 interval	[102].	Similarly,	 in	a	cohort	of	112	patients	with	liver	biopsies,	
Peterson	et	al	found	that	there	was	a	correlation	between	increasing	weight	and	degree	of	fatty	
liver	only	in	patients	who	were	overweight	and	had	a	moderate	alcohol	consumption	[110].	
	
Not	all	histological	studies	have	found	this	association.	Studying	a	group	of	132	morbidly	obese	
individuals	undergoing	bariatric	surgery	Cotrim	et	al	identified	no	relationship	between	alcohol	
consumption	and	histological	liver	injury.	An	effect	possibly	explained,	at	least	in	part,	by	their	
observation	 that	 there	 was	 as	 inverse	 relationship	 between	 insulin	 resistance	 and	 light	 to	
moderate	 alcohol	 consumption	 [111].	 Similarly,	 Dixon	 et	 al	 reported	 a	 lower	 prevalence	 of	
steatohepatitis	 amongst	 morbidly	 obese	 patients	 reporting	 moderate	 alcohol	 consumption,	
although	 this	 finding	 was	 not	 sustained	 in	 a	 multivariate	 analysis	 controlling	 for	 insulin	
resistance	 [112].	 Kwon	et	 al.	 found	 that	 regular	 alcohol	 consumption	during	overall	 reported	
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‘life-time’	exposure	in	patients	with	fatty	liver	was	associated	with	less	severe	disease	[113].	A	
publication	 from	 the	 NIH	 NASH	 Clinical	 Research	 Network	 suggested	 that	 modest	 alcohol	
consumption	was	associated	with	favourable	hepatic	histology	in	NAFLD	patients.	However	the	
study	was	 limited	to	 individuals	drinking	<20	grams/day	and	excluded	binge	drinkers	or	those	
with	any	history	of	previous	higher	alcohol	consumption	[114].	In	a	recent	study,	Hagstrom	et	al	
examined	 the	 impact	 of	 lifetime	 alcohol	 consumption	 on	 fibrosis	 severity	 in	 NAFLD	 in	 a	
prospective	 study	 involving	 120	 subjects	with	 biopsy	 proven	NAFLD.	 They	 concluded	 lifetime	
alcohol	 consumption	 with	 up	 to	 13	 units/week	 was	 associated	 with	 lower	 fibrosis	 stage	 in	
NAFLD.	However,	the	same	study	did	find	that	an	elevated	level	of	phosphatidyl	ethanol	(PEth),	
serving	 as	 a	biomarker	 for	 recent	 alcohol	 consumption,	was	 associated	with	higher	 stages	of	
fibrosis	and	so	these	data	require	further	clarification[115].		
	
From	these	studies,	 it	would	appear	that	alcohol	consumption	may	have	mixed	effects.	These	
data	should	be	interpreted	with	caution	however.	The	vast	majority	of	studies	have	been	cross-
sectional,	limiting	the	ability	to	assess	temporal	associations,	and	have	often	failed	to	consider	
potential	sources	of	bias	and	error.	 It	 is	 important	to	appreciate	that	moderate	alcohol	use	 is	
not	randomly	distributed	among	patients	with	NAFLD.	Various	lifestyle	factors	(socioeconomic	
status,	education,	co-morbid	conditions,	sex,	race,	previous	history	of	alcohol	excess)	affect	the	
pattern	of	alcohol	use	and	the	severity	of	underlying	liver	disease	[16,	116-118].	Not	adjusting	
for	 these	 factors	 could	 lead	 to	 confounding	 and	 an	 overestimation	 of	 benefits	 from	 low	 to	
moderate	 alcohol	 consumption.	 Indeed,	 a	 recent	 critical	 review	 of	 the	 effect	 of	 moderate	
alcohol	 consumption	 on	 cardiovascular	 and	 liver	 disease	 in	 patients	 with	 NAFLD	 (seven	
observational	 studies)	 concluded	 that	 no	 strong	 recommendation	 to	 support	 the	 benefit	 of	
moderate	alcohol	use	could	be	made	due	to	significant	methodological	limitations	in	the	source	
data	[119].	Furthermore,	it	is	doubtful	that	there	is	a	protective	effect	of	MAC	in	patients	with	
pre-existing	 underlying	 liver	 disease.	 Indeed,	 a	 retrospective	 cohort	 study	 provided	 evidence	
that	subjects	consuming	moderate	to	heavy	amounts	of	alcohol	with	severe	liver	fibrosis	have	
an	increased	risk	of	developing	hepatocellular	carcinoma	(HCC)	[120].		
	
Crucially,	 the	 level	at	which	any	potentially	beneficial	effect	derived	from	the	consumption	of	
alcohol	shifts	to	become	clearly	harmful	is	neither	consistent	nor	clearly	defined	with	sufficient	
accuracy	in	patients	that	have	co-existent	features	of	the	metabolic	syndrome.		
	
4.2.3. The	Effects	of	Obesity,	T2DM	and	the	Metabolic	Syndrome	on	ALD	
Boyle	et	al	 	 Page	13	of	38	
The	available	evidence	supports	the	view	that	obesity	confers	a	predisposition	to	development	
of	both	ALD	[100]	and	NAFLD	[121].	Whilst	obesity	per	se	 is	not	directly	associated	with	more	
advanced	hepatic	fibrosis	stage	in	patients	with	NAFLD	[122],	a	higher	BMI	has	been	found	to	
associated	with	more	 advanced	hepatic	 fibrosis	 in	ALD	 [100,	 101].	 Insulin	 resistance	 (IR)	 and	
T2DM	 are	 generally	 considered	 key	 components	 of	 the	 metabolic	 syndrome	 [123]	 that	 are	
strongly	associated	with	NAFLD	development	[24,	112,	121].	There	is	also	mounting	evidence	of	
a	 close	 relationship	 with	 ALD	 [124]	 and	 that	 the	 metabolic	 syndrome	 and/or	 T2DM	 may	
promote	 the	 development	 of	 ALD	 [24].	 A	 large	 cohort	 study	 found	 that	 IR/T2DM	 was	 an	
independent	predictor	of	overall	and	liver-related	mortality	in	ALD	and	NAFLD	patients	[125].	A	
recent	 study	 reported	 no	 significant	 difference	 in	 post-transplant	 survival	 or	 CVD	 mortality	
amongst	patients	with	NASH-related	or	ALD	cirrhosis	[126].		
	
Amongst	 patients	 with	 high	 alcohol	 consumption,	 obesity	 is	 an	 independent	 risk	 factor	 for	
acute	 alcoholic	 hepatitis	 and	 cirrhosis	 [100,	 101].	 It	 has	been	demonstrated	 that	 alcohol	 and	
obesity/T2DM	 confer	 quantitative	 and	 qualitative	 changes	 to	 the	 intestinal	 microbiome	 and	
impair	the	intestinal	barrier	thus	promoting	steatohepatitis	and	fibrosis	[127,	128].	Obesity	and	
alcohol	also	reduces	adipokine	production	in	visceral	adipose	tissue.	Adiponectin	(anti-fibrotic)	
is	reduced	in	individuals	with	obesity	or	sustained	high	alcohol	consumption	[69,	129,	130].		
	
In	a	 recent	 study	of	107,735	middle-aged	Korean	men	who	participated	 in	a	postal	 survey	 in	
2004	and	then	followed	for	6	years,	each	5-drink	higher	alcohol	use	increment	was	associated	
with	 increased	 risk	 of	 non-neoplastic	 liver	 disease	mortality.	 In	 this	 population,	 low	BMI	was	
generally	associated	with	higher	mortality.	However,	amongst	those	with	a	BMI	≥25 kg/m2,	each	
5 kg/m2	 increment	 was	 also	 associated	 with	 an	 elevated	 mortality	 from	 non-neoplastic	 liver	
diseases	[131].	In	a	large	French	study,	1,604	alcoholics	were	evaluated	to	determine	whether	
obesity	 was	 a	 risk	 factor	 for	 the	 development	 of	 ALD.	 They	 reported	 that	 being	 obese	 or	
overweight	were	 independent	 risk	 factors	 for	 fatty	 liver	 (402	 cases)	 and	 cirrhosis	 (608	 cases)	
among	various	stages	of	ALD.	Specifically,	being	overweight	for	more	than	10	years	 increased	
the	likelihood	of	steatosis,	alcoholic	hepatitis	and	cirrhosis	by	2.5-,	3-	and	2.15-fold	compared	
to	a	patient	who	was	not	overweight	after	adjustment	for	other	variables	[100].		
	
4.2.4. The	effects	of	Alcohol	and	on	Metabolic	Syndrome	on	HCC	Development	
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One	of	the	first	studies	to	observe	the	effects	of	varying	levels	of	alcohol	consumption	on	the	
development	of	HCC	in	patients	with	radiologically	confirmed	hepatic	steatosis	was	conducted	
in	 Japan.	 [132].	 The	 incidence	of	HCC	after	 long-term	 follow-up	 in	 these	patients	was	0.28%,	
with	 an	 annual	 incidence	 of	 0.05%.	 The	 incidence	 of	 HCC	 related	 with	 high-intermediate	
ethanol	 intake	 and	 FLD	 was	 0.63%	 with	 an	 annual	 rate	 of	 0.16%.	 The	 risk	 of	
hepatocarcinogenesis	was	 increased	 significantly	 by	 a	 daily	 ethanol	 consumption	 >40	 g,	with	
the	 risk	 of	 hepatocarcinogenesis	 associated	 with	 a	 high-intermediate	 to	 excessive	 level	 of	
ethanol	 consumption	 being	 almost	 2–12	 times	 higher	 than	 that	 observed	 in	 patients	 with	 a	
daily	ethanol	consumption	of	<40	g.	These	findings	are	supported	by	a	recent	Japanese	study	
where	 researchers	 reported	 a	 synergistic	 effect	 of	 obesity	 and	 alcohol	 consumption	 on	
hepatocarcinogenesis	 in	 patients	 positive	 for	 the	 hepatitis	 B	 virus	 antigen	 [133].	 The	 group	
identified	serum	GGT	as	a	risk	factor	for	the	development	of	HCC,	 leading	to	speculation	that	
ethanol	consumption	may	be	a	major	factor	in	the	cause	of	this	malignancy.	
	
Studies	have	shown	that	alcohol	use	and	obesity	demonstrate	a	synergistic	association.	The	risk	
of	incident	HCC	in	a	large	study	from	Taiwan	(N=	23,712)	among	alcohol	drinkers	showed	that	
the	 cumulative	 risk	 of	 HCC	 in	 non-obese	 subjects	 was	 2.7%	 compared	 to	 8.7%	 in	 obese	
participants	 [94].	 The	 subjects	 were	 followed	 up	 for	 11.6	 years.	 On	 analysis	 investigators	
determined	that	obesity	increased	the	risk	of	incident	HCC	by	3.82-fold	[94].	It	is	proposed	that	
visceral	obesity	 increases	 lipid	peroxidation	and	production	of	 inflammatory	 cytokines,	which	
may	 contribute	 to	 the	 progression	 of	 NAFLD	 and	 ALD	 to	 cirrhosis	 and	 its	 complications,	
including	HCC	[134].	In	addition	to	lipid	peroxidation	and	pro-inflammatory	cytokines,	variants	
in	PNPLA3	also	have	been	associated	with	increased	risk	of	HCC	in	NAFLD	and	ALD	[135-137].	In	
a	case-controlled	study	by	Lok	et	al,	the	authors	reported	an	approximate	6-fold	increased	risk	
of	HCC	with	 alcohol	 consumption	 (compared	 to	 a	 5-fold	 risk	with	 tobacco	and	4-fold	 risk	 for	
obesity)	 among	 Americans	 with	 cirrhosis	 [138].	 Table	 5	 provides	 a	 summary	 of	 the	
epidemiological	 and	 experimental	 evidence	 of	 the	 combined	 effects	 of	 alcohol	 and	
adiposity/obesity	on	HCC	risk.		
	
4.3. Influence	of	Metabolic	Syndrome	and	Alcohol	Consumption	on	Extra-Hepatic	
Disease	
It	is	well	accepted	that	NAFLD	and	the	wider	metabolic	syndrome	are	associated	with	a	range	of	
extra-hepatic	disease	manifestations,	in	particular	T2DM	and	cardiovascular	disease	(reviewed	
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[139]).	 It	 is,	 at	 least	 in	 part,	 due	 to	 a	 putative	 cardio-protective	 effect	 that	 modest	 alcohol	
consumption	has	been	supported	by	some	clinicians.		
	
Epidemiological	studies	have	suggested	that	consumers	of	moderate	 levels	of	alcohol	have	a	
lower	 risk	of	 T2DM	compared	with	non-drinkers	 [140-142].	 In	 a	 recent	Danish	 cohort	 study,	
the	lowest	risks	of	diabetes	were	reported	in	men	who	consumed	14	drinks/week	and	women	
who	 consumed	9	drinks/week	 [85].	 Furthermore,	 findings	 from	a	meta-analysis	based	on	13	
prospective	studies	showed	that	wine	consumption	was	associated	with	a	significantly	 lower	
risk	of	T2DM:	20%	risk	reduction	at	20–30	g	pure	alcohol/day	[143].		
	
A	 cross-sectional	 study	 of	 patients	with	 NAFLD	 by	 Sinn	 et	 al	 reported	moderate	 alcohol	 use	
(<20 g/day)	was	associated	with	decreased	odds	of	carotid	plaque	(OR	0.74;	95%	CI	0.60-0.92)	
and	carotid	stenosis	(OR	0.62;	95%	CI	0.43-0.90)	compared	to	non-drinkers	[144].	Results	were	
adjusted	for	smoking,	metabolic	syndrome	and	age	however	socioeconomic	status	and	physical	
activity	were	not	considered.	[144].	Several	other	studies	also	report	decreased	mortality	with	
MAC	[145-147].	However,	a	meta-analysis	by	Carrao	et	al	that	reviewed	data	from	case	control	
and	cohort	 studies	concluded	 that	 the	protective	effects	of	moderate	alcohol	 intake	 lacked	a	
sufficiently	clear	definition	of	the	dose	of	alcohol	consumed	or	an	accurate	estimate	of	the	size	
of	the	derived	protective	effect.	Publication	bias	was	recognised	as	responsible	for	a	potential	
overestimation	 of	 the	 reported	 effects	 and	 it	 was	 noted	 that	 studies	 displayed	 substantial	
heterogeneity	 with	 gender	 significantly	 modifying	 the	 shape	 of	 the	 dose	 response	
function[148].		
	
5. Practical	issues	for	clinicians		
In	 clinical	 practice,	 in	 a	patient	with	 a	 fatty	 liver,	 it	 can	be	difficult	 to	determine	 the	 relative	
contributions	of	alcohol	consumption	and	the	metabolic	syndrome	when	both	risk	factors	are	
present.		Indeed,	it	is	well	recognised	that	even	amongst	patients	referred	to	a	liver	clinic	with	a	
diagnosis	 of	 NAFLD,	 their	 alcohol	 consumption	 is	 often	 significantly	 higher	 than	 initially	
recognised	 [149].	 Therefore,	 the	 possibility	 of	 the	 combined	 effects	 of	 alcohol	 and	 the	
metabolic	syndrome	should	be	considered	in	all	patients	with	suspected	NAFLD.		In	particular,	
consideration	 should	 be	 given	 to	 the	 role	 of	 biomarkers	 and	 universal	 screening	 for	
identification	of	risky,	often	under-reported,	alcohol	consumption.	
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5.1.	Detecting	alcohol	excess:	biomarkers	
	
Some	 patients	 may	 exhibit	 physical	 signs	 that	 might	 suggest	 harmful	 alcohol	 use	 or	
complications	 of	 the	 metabolic	 syndrome.	 	 Routine	 laboratory	 tests,	 including	 Mean	
Corpuscular	 Volume	 (MCV),	 gamma	 glutamyl	 transpeptidase	 (GGT)	 and	 the	 aspartate	
aminotransferase/alanine	 aminotransferase	 (AST/ALT)	 ratio	 can	 indicate	 excessive	 alcohol	
consumption,	though	their	specificity	is	limited	[150].	Whilst	GGT	remains	a	commonly	adopted	
surrogate	for	the	detection	of	alcohol	excess,	it	is	actually	a	poor	indicator	of	excessive	alcohol	
consumption	 as	 levels	 may	 be	 increased	 by	 other	 factors	 such	 as	 obesity	 [151]	 and	 can	 be	
elevated	 in	 patients	with	 advanced	 fibrosis,	 regardless	 of	 aetiology	 [152].	 Likewise,	whilst	 an	
increased	AST/ALT	ratio	was	historically	thought	to	be	indicative	of	excess	alcohol	[153],	more	
recently	 this	 has	 been	 realised	 as	 a	marker	 of	 advanced	 fibrosis	 [154,	 155].	 Conversely,	 the	
effect	 of	 alcohol	 consumption	 on	 the	 AST/ALT	 ratio	 confounds	 simple	 non-invasive	 fibrosis	
scores	 that	 have	 been	 validated	 for	 the	 non-invasive	 assessment	 of	 NAFLD	 [156].	 Therefore,	
such	 scores,	 including	 the	FIB-4	and	NAFLD	 fibrosis	 scores	 cannot	meaningfully	be	applied	 to	
heavy	alcohol	drinkers	[157,	158].	The	ratio	may	also	be	influenced	by	age	[159].		
The	detection	of	alcohol	in	blood	(or	breath)	is	the	most	direct	method	of	alcohol	detection	but	
is	valid	only	for	recent	consumption,	given	its	rapid	clearance[160].	In	an	effort	to	extend	this	
narrow	detection	window,	indirect	markers	of	alcohol	markers	are	increasingly	used.		Amongst	
these,	 Carbohydrate	 deficient	 transferrin	 (CDT)	 is	 reported	 to	 have	 the	 best	 sensitivity	 and	
specificity	for	regular	long-term	excessive	alcohol	consumption	and	can	be	used	to	differentiate	
between	heavy	drinking	and	abstinence,	often	amongst	populations	who	are	required	to	prove	
abstinence	 [150,	 161].	 However,	 CDT	 results	 can	 be	 confounded	 by	 obesity,	 with	 lower	 CDT	
levels	being	found	in	obese	compared	to	non-obese	subjects	that	consume	similar	amounts	of	
alcohol	 [162].	 Alcohol	 metabolites,	 notably	 ethyl-glucuronide	 (EtG)	 and	 ethyl-sulfate	 can	 be	
measured	 in	 the	urine	 for	 several	days	after	alcohol	 consumption	 [163].	 	However,	 these	are	
not	 widely	 available	 and	 have	 primarily	 been	 used	 to	 help	 prove	 or	 disprove	 self-reported	
abstinence	 in	 targeted	 alcohol	 assessments	 [164].	 Little	 is	 known	 about	 their	 application	 or	
validation	 amongst	 patients	with	 fatty	 liver,	more	 generally.	 	 Therefore,	 no	 single	 laboratory	
marker	 can	 definitively	 establish	 the	 relative	 contribution	 from	 alcohol	 consumption	 or	
metabolic	risk	factors.		
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5.2.	Screening	for	risky	alcohol	consumption	
Indeed,	 in	detecting	 risky	alcohol	 consumption,	 there	 is	 considerable	evidence	 that	 screening	
tools	are	more	effective	than	biochemical	markers	of	alcohol	use	[165].	Several	screening	tools	
have	 been	 developed	 to	 identify	 adults	 with	 risky	 alcohol	 drinking	 and	 alcohol	 dependence.		
Amongst	 these,	 the	 best	 validated	 is	 the	 Alcohol	 Use	 Disorders	 Identification	 Test	 (AUDIT),	
developed	 by	 the	 World	 Health	 Organisation	 [166].	 These	 screening	 tools	 can	 be	 used	
effectively	to	identify	and	intervene	with	risky	alcohol	consumption	[167].		However,	they	have	
variable	 sensitivity	 depending	 on	 the	 population	 being	 screened	 and	 the	 validity	 of	 alcohol	
screening	 tools	 amongst	 patients	 with	 combined	 alcohol	 and	 metabolic	 risk	 factors	 has	 not	
specifically	been	studied.			
	
5.3.	Weight	loss	surgery	
A	specific	clinical	scenario	in	which	effective	alcohol	screening	is	even	more	topical,	is	amongst	
patients	undergoing	weight	loss	surgery	for	the	management	of	their	NAFLD/NASH.		Soon	after	
the	advent	of	bariatric	surgery,	concerns	emerged	that	some	patients	may	have	an	 increased	
tendency	 to	 develop	 post-operative	 alcohol	 use	 disorders	 (AUD).	 This	 may	 relate	 to	
pharamacokinetic	 changes,	 with	 accelerated	 alcohol	 absorption	 after	 bariatric	 surgery	
compared	to	controls	or	pre-operatively	[168,	169].		Additionally,	this	has	been	conceptualised	
as	 ‘addiction	 transfer’,	 behavioural	 subsitution	 of	 drinking	 alcohol	 rather	 than	 eating	 [170].		
Initial	 reports	 provided	 conflicting	 assessments	 of	 the	 risk	 of	 post-operative	 AUD	 but	 were	
limited	by	small	sample	sizes	in	retrospective	analyses	[171-173]		
More	 recently,	 robust	 prospective	 data	 has	 been	 provided	 by	 the	 large	 US	 multi-center	
longitudinal	assessment	of	bariatric	surgery	cohort	study.	 	A	significantly	higher	prevalence	of	
AUD	was	identified	after	the	second	post-operative	year,	compared	with	the	year	immediately	
before	and	after	surgery	[174].	 	Subsequent	extension,	with	follow-up	to	7	years,	confirmed	a	
high	prevalence	of	AUD	post-operatively.		In	particular,	one-fifth	of	those	undergoing	Roux-en-Y	
gastric	 bypass	 developed	 AUD	within	 5	 years	 of	 surgery,	 which	 was	 twice	 the	 rate	 of	 those	
undergoing	 laparasopic	 adjustable	 gastric	 banding	 [175].	 	 Similar	 results	 have	 been	 reported	
from	a	large	retrospective	population-based	cohort	study	including	all	patients	who	underwent	
weight	 loss	 surgery	 in	 Sweden	 [176]	 and	 in	 some	 smaller	 prospective	 studies	 [177,	 178].		
Therefore,	patients	 in	whom	weight	 loss	surgery	 is	being	considered,	or	has	been	performed,	
require	careful	evaluation	with	respect	to	screening	for	risky	alcohol	consumption.				
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5.4.	Nutritional	support	in	the	setting	of	Alcohol	or	Nicotine	Use	Disorders	
Overlap	exists	between	obesity	and	alcohol	and/or	nicotine	use,	where	weight	gain	has	been	
observed	 in	 patients	 with	 ALD	 that	 stop	 drinking	 or	 among	 ex-smokers	 [179-182].	 Potential	
benefits	 may	 therefore	 be	 derived	 by	 providing	 combined	 nutritional	 and	 substance	 abuse	
counselling	 in	 patients	 with	 fatty	 liver	 disease.	 Chemically,	 there	 are	 similarities	 between	
alcohol	 abuse	 and	 obesity	 centred	 around	 dopamine	 activity	 [183].	 A	 reduced	 numbers	 of	
dopamine	(D2)	receptors	in	the	brain	of	obese	individuals	and	those	with	chronic	alcohol	abuse	
have	 been	 observed	 [184,	 185].	 This	 receptor	 deficiency	 is	 thought	 to	 drive	 a	 compulsive	
engagement	in	pleasurable	behaviours,	such	as	alcohol	use	and	eating	i.e.	a	“Reward	Deficiency	
Syndrome”	 [186,	 187].	 Another	 prominent	 neurotransmitter	 is	 leptin.	 During	 alcohol	
withdrawal,	 leptin,	 although	 primarily	 associated	 with	 food	 intake	 regulation,	 has	
demonstrated	 increased	 levels	 correlating	 with	 the	 increased	 intensity	 of	 alcohol	 cravings	
during	this	period.	A	concept	has	emerged	that	leptin	interacts	with	the	brain	reward	system	in	
producing	 its	 effects	 on	 both	 food	 and	 alcohol	 intake	 [188].	 However,	 despite	 the	 level	 of	
evidence	that	would	suggest	the	potential	value	of	combined	nutrition	and	alcohol	counselling	
in	 primary	 care	 practices	 this	 is	 something	 that	 is	 not	 routinely	 offered.	 Indeed,	 it	 is	 still	
uncommon	for	substance	disorder	treatment	facilities	to	offer	nutrition	or	 lifestyle	education.	
In	a	study,	where	nutrition	education	was	provided	to	men	in	a	residential	treatment	program	
the	outcome	was	reduced	weight	gain	during	recovery	[189].	Regarding	nicotine	addiction,	data	
has	 shown	 that	 levels	 of	 overweight	 and	 obesity	 peak	 in	 middle	 age	 (45–64	 years)	 which	
overlaps	with	the	period	when	smoking	cessation	is	more	likely	to	occur	[190].	In	a	population	
study	 of	 middle	 aged	 men,	 44%	 of	 overweight	 men	 and	 48%	 of	 obese	 men	 were	 former	
smokers	[190].	The	corollary,	therefore,	is	that	weight	gain	may	partially	counteract	the	accrued	
health	benefits	of	quitting	smoking	by	contributing	to	an	increased	risk	of	metabolic	syndrome	
development,	which	demonstrates	a	strong	association	with	CVD	and	NAFLD.	[191,	192]		
	
In	clinical	practice,	 the	evaluation	of	all	patients	with	suspected	NAFLD,	 including	those	being	
considered	 for	 weight	 loss	 surgery,	 should	 include	 careful	 screening	 for	 at-risk	 alcohol	
consumption,	 with	 defined	 clinical	 pathways	 to	 intervene,	 refer	 and	 treat	 when	 AUD	 is	
detected.	 In	 order	 to	 optimise	 the	 health	 benefits	 of	 both	 excessive	 alcohol	 cessation	 and	
smoking	cessation	in	the	setting	of	fatty	liver	disease,	a	better	understanding	of	the	behavioral	
relationships	between	smoking,	alcohol	consumption	and	dietary	habits	 is	needed	 in	order	to	
prevent	weight	gain.	 
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6. Conclusions	
ALD	and	NAFLD	are	the	two	most	 frequent	 liver	diseases	worldwide.	 It	 is	also	clear	that	both	
conditions	may	co-exist	to	varying	degrees	in	a	significant	number	of	patients.	There	is	strong	
epidemiological	 and	 experimental	 evidence	 that	 alcohol	 and	 components	 of	 the	 metabolic	
syndrome	 exert	 synergistic	 effects	 promoting	 liver	 injury	 and	 progression	 towards	 cirrhosis.	
When	considering	the	impact	of	alcohol	as	a	cofactor	for	steatosis	and	fibrosis	in	patients	with	
metabolic	syndrome,	 it	 is	astute	to	critically	assess	the	degree	of	overlap	that	exists	between	
NAFLD	 and	 ALD.	 At	 present,	 clinicians	 may	 find	 it	 necessary	 to	 assign	 both	 aetiologies	 to	 a	
patient	 in	 their	 medical	 records	 to	 ensure	 appropriate	 long-term	 consideration	 of	 the	
complications	relating	to	both	alcohol	consumption	and	the	metabolic	syndrome.	However,	in	
light	of	the	rising	prevalence	of	metabolic	syndrome,	NAFLD	and	ALD,	the	plausible	concept	of	
“dual-aetiology	 fatty	 liver	 disease”	 may	 serve	 as	 a	 more	 tractable	 diagnostic	 category	 that	
reflects	 the	 co-existence	 of	 these	 diverse	 processes	 in	 patients	 with	 fatty	 liver	 disease	 and	
higher-than-recommended	 alcohol	 consumption	 that	 however	 falls	 short	 of	 a	 clear	 ALD	
diagnosis.	This	construct	opens	up	multiple	questions	of	clinical	relevance	that	we	have	alluded	
to	 in	this	review.	For	example,	the	need	to	critically	examine	the	hepatotoxic	dose	thresholds	
for	 alcohol	 and	 the	 guideline	 recommendations	 for	 ‘safe’	 alcohol	 consumption,	 which	 in	
addition	 to	 gender	 should	 also	 take	 into	 account	 the	 presence	 of	 overweight/obesity.	 The	
future	 research	 agenda	 remains	 open,	 looking	 for	 answers	 from	 prospective	 cohort	 studies,	
elucidating	the	exact	role	and	interaction	of	ethanol	consumption	and	features	of	the	metabolic	
syndrome	on	liver	injury.		
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Figure	1:	Shared	Pathogenic	Mechanisms	in	NAFLD	and	ALD	
The	pathogenesis	of	NAFLD	and	ALD	 share	many	 common	 factors	 that	 combine	 in	 varying	degrees	 to	
drive	 disease	 progression.	 These	 include	 the	 role	 of	 Free	 Fatty	 Acids,	 FFA	 oxidation,	 reactive	 oxygen	
species,	 endoplasmic	 reticulum	 stress,	 genetics/epigenetics,	 the	 innate	 immune	 system,	 gut	 derived	
endotoxins,	endogenous	alcohol,	intestinal	dysbiosis	and	small	intestinal	bacterial	overgrowth	(SIBO).		
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Table	1:	Studies	using	in	vivo	and	ex	vivo	models	to	explore	the	interaction	of	NAFLD	and	ALD	
	
Study	 Key	reported	findings	
Karsenty	et	al,	1985	[193]	 Hepatic	lipogenesis	and	fatty	degeneration	reduced	in	obese	(fa/fa)	rats	given	an	ethanol	diet	showing	a	paradoxical	effect	of	ethanol	on	liver	
lipogenesis	in	the	genetically-obese	Zucker	rat	
Carmiel-Haggai	 et	 al,	 2003	
[194]	
Binge	ethanol	exposure	increases	liver	injury	in	obese	rats	
Olleros	et	al,	2008	[195]	 Moderately	 FAT	 diet	 and	 low-dose	 EtOH	 generate	 steatohepatitis	 and	 TNF	 liver	 expression.	 Changes	 in	 regulation	 of	 TNF	 associated	 with	
increased	IL-6,	IFN-gamma	and	iNOS	expression. 
Wang	et	al.	2009	[196]	 Ethanol-induced	cytochrome	P4502E1	causes	carcinogenic	etheno-DNA	lesions	in	alcoholic	liver	disease.		
Wang	et	al,	2010	[197]	 Moderate	alcohol	consumption	aggravates	high-fat	diet	induced	steatohepatitis	in	rats.	
Gabele	at	al,	2011	[198]	 In	combination	with	High	fat	diet,	alcohol	significantly	enhanced	proinflammatory	and	pro-fibrotic	gene	expression,	stellate	cell	activation,	ECM	
deposition	compared	to	the	HF	diet	alone.		
Xu	et	al,	2011	[199]	 Synergistic	steatohepatitis	by	moderate	obesity	and	alcohol	in	mice	despite	increased	adiponectin	and	p-AMPK.		
Everitt	et	al,	2013	[200]	 Ethanol	administration	to	obese	mice	exacerbates	fatty	liver	via	impairment	of	the	hepatic	lipid	metabolism	pathways.	This	effect	is	mediated	
via	SIRT1-AMPK	signalling.	
Nascimento	 et	 al,	 2013	
[201]	
Aggravation	of	NASH	by	moderate	alcohol	consumption	is	associated	with	lower	SIRT1	activity	in	rats.		
Duryee	et	al,	2014	[202]	 Precision-cut	liver	slices	from	diet-induced	obese	rats	exposed	to	ethanol	are	susceptible	to	oxidative	stress	and	increased	fatty	acid	synthesis.		
Minato	et	al,	2014	[203]	 Binge	alcohol	consumption	aggravates	oxidative	stress	and	promotes	pathogenesis	of	NASH	from	obesity-induced	simple	steatosis.	
Alwahsh	et	al,	2014	[204]	 Combination	of	alcohol	and	fructose	exacerbates	metabolic	imbalance	in	terms	of	hepatic	damage,	dyslipidaemia,	and	insulin	resistance	in	rats.		
Chang	et	al,	2015	[205]	 Short-	or	long-term	high-fat	diet	consumption	combined	with	an	acute	ethanol	binge	synergistically	induces	liver	injury	in	mice.	CXCL1	plays	an	
important	role.		
Duly	et	al,	2015	[90]	 Alcohol	 and	 high	 fat	 diet	 produced	 maximum	 hepatic	 steatosis,	 increased	 micro-	 and	 macro-vesicular	 lipid	 droplets,	 increased	 de	 novo	
lipogenesis	and	decreased	fatty	acid	β-oxidation;	with	increased	inflammation	and	fibrogenesis	in	mice	livers.	
Song	et	al,	2016	[206]	 Chronic	alcohol	consumption	promotes	liver	damage	in	high-fructose	diet	fed	mice	due	to	an	increased	inflammatory	response.		
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Table	2:	Epidemiological	studies	Showing	a	Negative	Effect	of	light/moderate	alcohol	consumption	on	Liver	Disease	
	
Study	 Study	
Number	
Type	of	Study	 Country	 Diagnosis	of	
fatty	liver	
Alcohol	consumption	categories	 Key	reported	findings	
Petersen,	
1977	[110]	
112		
	
Retrospective	 Denmark	 Biopsy	
	
Moderate	alcohol	>	five	drinks	per	day	
for	more	than	two	years	
Higher	frequency	of	fatty	liver	was	found	to	occur	in	
cases	of	moderate	alcohol	consumption	alone,	or	when	
combined	overweight	and	obesity	
Bellentani	et	
al,	2000	[96]	
257	 Cross-sectional	 Italy	 Ultrasound	 No	alcohol	
Heavy	alcohol	>40g/week	
The	risk	of	steatosis	by	abdominal	US	was	increased	by	
2.8-fold	in	heavy	drinkers,	4.6-fold	in	individuals	with	
obesity,	and	by	5.8-fold	in	those	with	both	obesity	and	
heavy	alcohol	use	
Ruhl	et	al,	
2005	[97]	
13,580	 Cross-sectional	 USA	 Elevated	
ALT/AST	
Moderate	alcohol	consumption	>2	
drinks	
Raised	ALT	amongst	obese	consumers	of	1-2	drinks/day.	
Alatalo	et	al,	
2008	[98]	
2164	 Cross-sectional	 Finland	 Elevated	
ALT/AST	
	
Moderate	alcohol	<40	g	per	day	 The	effect	of	moderate	alcohol	consumption	on	liver	
enzymes	increases	with	increasing	BMI	
Loomba	et	al,	
2009	[99]	
2364		 Cross-sectional	 USA	 Elevated	
ALT/AST	
	
Moderate	alcohol	>3	drinks/day	 8.9-fold	increased	risk	of	raised	ALT	21-fold	risk	of	raised	
AST	in	obese	consuming	>3	alcoholic	drinks/day	
Lau	et	al,	2015	
[207]	
4009	 Cross-sectional	 Germany	 Ultrasound	 Low-risk	drinking	(women:	1-20	g,	
men:	1-40	g),	medium-risk	(women:	
21-40	g,	men:	41-60	g)	and	high-risk	
(women:	>40	g,	men:	>60	g)	
Steatosis	risk	increased	with	increasing	levels	of	average	
daily	alcohol	consumption/binge	drinking	in	
combination	with	adiposity.		
OR:	Odds	Ratio;	95%CI:	95%	Confidence	interval;	MAC:	moderate	alcohol	consumption	
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Table	3:	Epidemiological	studies	Showing	a	Beneficial	Effect	of	light/moderate	alcohol	consumption	on	Liver	Disease	
	
Study	 Study	
Participants	
Type	of	Study	 Country	 Diagnosis	of	
fatty	liver	
Alcohol	consumption	categories	 Key	reported	findings	
Suzuki	et	al,	
2007	[208]	
1177	 Cross-sectional	 USA	 ALT/AST	 None	or	minimal	<70	g/wk,	light	>	70	g	
and	<140	g/wk,	moderate	>	140	g	and	
<280	g/wk,	excessive	>	280	g/wk	
MAC	associated	with	decreased	incidence	of	hyper-
transaminasemia	(adjusted	hazard	ratio	0.4	[0.1-0.9],	
P=	0.02]	
Dunn	et	al,	
2008	[209]	
8156	 Cross-sectional	 USA	 Elevated	ALT	
	
Moderate	alcohol	consumption	>	
10g/day	
NAFLD	in	3.2%	of	non-drinkers	and	0.4%	of	modest	
wine	drinkers.	OR	0.15	(0.05-0.49).		
Gunji	et	al,	
2009	[210]	
7431	 Cross-sectional	 Japan	 Ultrasound	 Light	(40-140	g/week)	and	moderate	
(140-280	g/week)	alcohol	
consumption	
Light	and	moderate	alcohol	consumption	
independently	reduced	likelihood	of	fatty	liver		
(OR=0.824	and	0.754,	(0.683-0.994)	and	0.612-0.928,	
P=0.044	and	0.008,	respectively	
Yamada	et	al,	
2010	[211]	
63447		 Cross-sectional	 Japan	 Ultrasound	 Moderate	drinkers	>23	g/day,	heavy	
drinkers	>46	g/day		
Daily	moderate/heavy	alcohol	consumption	protective	
in	men	
Shen	et	al,	
2010	[212]	
500	 Retrospective	
cohort	
China	 Abnormal	
liver	
enzymes		
Moderate	alcohol	<40	g/day	 No	significant	dose-response	relationship	between	
daily	alcohol	intake/duration	of	drinking	and	raised	
ALT	or	AST.	
Hiramine	et	al,	
2011	[213]	
9886	 Cross-sectional	 Japan	 Ultrasound	 Non-,	light-,	moderate-,	and	heavy-
drinkers	(0,	<20,	20-59	and	≥60	g/day)	
The	prevalence	of	FL	was	associated	positively	with	
body	mass	index	and	inversely	with	alcohol	
consumption	(light,	OR	0.71	[95%CI	0.59-0.86];	
moderate,	OR	0.55	[CI	0.45-0.67];	heavy,	OR	0.44	[CI	
0.32-0.62])	
Moriya	et	al,	
2011	[214]	
7112	 Cross-sectional	 Japan	 Ultrasound	 None:	0.1–69.9	g/week,	70.0–139.9	
g/week,	140.0–279.9	g/week,	and	⩾280.0	g/week	 Alcohol	consumption	inversely	associated	with	steatosis	(OR	0.54	[95%CI	0.46-0.63]).		
Hamaguchi	et	
al,	2012	[215]	
18571	 Cross-sectional	 Japan	 Ultrasound	 Minimal	alcohol	consumption,	<	40	
g/wk;	light,40-140	g/wk;	moderate,	
140-280	g/wk;	and	excess,	>	280	g/wk	
OR	for	fatty	liver	<	1.0	in	men	with	any	level	of	alcohol	
consumption	and	in	women	with	light/moderate	
consumption.	
Wong	et	
al,2012	[216]	
922		 Cross-sectional	 Japan	 Proton-
Magnetic	
resonance	
spectroscop
y;	fibroscan	
Modest	drinkers	(<10	g	per	day)	 Modest	alcohol	consumption	does	not	increase	the	
risk	of	fatty	liver	or	hepatic	fibrosis	
Taniai	et	al,	
2012	[217]	
266	 Cross-sectional	 Japan	 Cirrhosis	
Biopsy/Imagi
Diagnosis	of	ALD	based	on	alcohol	
intake	(>70g/day	for	>5-years)	
The	prevalence	of	obesity	and	T2DM	similar	in	non-
cirrhotic	and	cirrhotic	female	ALD	patients	
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Sookoian	at	al,	
2014	[108]	
43175	 Meta-analysis	 Argentin
a	
Biopsy	 Non-drinkers:	0	g/day;	modest	
drinkers	<40	g/day		
MAC	confers	a	~31%	protective	effect	on	the	risk	of	
NAFLD.		
Moriya	et	al,	
2015	[218]	
5297	 Longitudinal	
study	
Japan	 Ultrasound	 None:	0.1-69.9	g/week,	70.0-139.9	
g/week,	140.0-279.9	g/week,	and	≥280.0	g/week.	 Light/moderate	alcohol	consumption	likely	to	protect	against	fatty	liver		
Takahashi	et	
al,	2015	[219]	
8029	 Cross-sectional	 Japan	 Ultrasound	 Non-drinkers	(<20	g	daily),	moderate	
drinkers	(20–50	g	daily),	or	heavy	
drinkers	(>50	g	daily).	
MAC	a	negative	risk	factor	for	fatty	liver	in	subjects	
with	BMI	≥25	(OR,	0.74	for	non-obese;	0.39	for	obese).	
Heavy	alcohol	intake	a	negative	risk	factor	in	obese	
males	(OR	0.62)	but	a	positive	risk	factor	in	non-obese	
males	(OR	1.29)	and	in	all	females	(OR	2.22	for	non-
obese	and	6.6	for	obese).	
OR:	Odds	Ratio;	95%CI:	95%	Confidence	interval;	MAC:	moderate	alcohol	consumption	
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Table	4:	Studies	Examining	the	Histological	effects	of	Alcohol	Consumption	on	Subjects	with	Confirmed	NAFLD	
	
Study	 Number	of	
participants		
Diagnosis	of	NAFLD	 Alcohol	consumption	categories	 Key	reported	findings	 Histology	
End-point	
Dixon	et	al,	
2001	[112]	
105	 Biopsies	at	obesity	
surgery	
Minimal	consumption	(20	g/week),	
moderate	>	20	g/week	and	
excessive	<	100	g/week	>	100	
g/week	
IR	(OR	9.3	[95%CI	3.4-26]),	hypertension	(OR	5.2	[95%CI	2.0-13.5]),	
raised	ALT	(OR	8.6	[95%CI	3.1-23.5])	independent	predictors	of	
NASH.	
NASH	
Ekstedt	et	
al,	2009	
[102]	
71	 Biopsy	based	on	elevated	
LFTS	
Low-risk	drinking	(women:	1–20	g,	
men:	1–40	g),	medium-risk	drinking	
(women:	21–40	g,	men:	41–60	g)	
and	high-risk	drinking	(women:	>40	
g,	men:	>60	g	
Mean	follow-up	13.8	years.	17	patients	(24%)	fulfilled	the	criteria	for	
significant	fibrosis	progression.	More	patients	reporting	heavy	
episodic	drinking	with	fibrosis	progression	and	trend	towards	higher	
weekly	alcohol	consumption.		
Fibrosis	
Cotrim	et	
al,	2009	
[111]	
132	 Obese	patients	
undergoing	liver	biopsy	at	
bariatric	surgery	
G1:	alcohol	intake	greater	than	20	
g/day	and	less	than	40	g/day;	G2:	
alcohol	intake	less	than	20	g/day;	
G3:	no	alcohol	intake	
MAC	may	have	a	protection	effect	against	IR	in	severely	obese	
patients	but	no	effect	on	liver	disease.	
NASH	
	
Fibrosis	
Dunn	et	al,	
2012	[114]	
682	 NIH	NASH	Clinical	
Research	Network	
	(1)	drinking	>20	g/day,	(2)	binge	
drinkers,	or	(3)	non-drinkers	with	
previous	alcohol	consumption	were	
excluded	
Reduced	risk	of	NASH	in	modest	drinkers	vs.	non-drinkers	(OR	0.56	
[95%CI	0.39-0.84]).	Likelihood	of	NASH	fell	as	alcohol	consumption	
increased	within	the	range	of	modest	consumption.	Modest	drinkers	
had	reduced	fibrosis	(OR	0.56	[0.41-0.77]),	and	hepatocellular	injury	
(OR	0.66	[0.48-0.92])	than	non-drinkers	
NASH	
	
Fibrosis	
Dunn	et	al,	
2012	[220]	
405	 Adult	car	accident	
autopsies	in	17	Kansas	
and	Missouri	counties	
from	2000	to	2010	
The	non-alcoholic	group	had	
undetectable	blood	alcohol	
concentration,	while	the	alcoholic	
group	had	a	blood	alcohol	
concentration	≥0.08%.	
Alcohol	had	3.5-fold	increase	[95%CI,	2.0-5.9],	while	every	5	kg/m2	
BMI	increase	had	1.9-foldincrease	[95%CI,	1.7-2.5]	risk	of	a	higher	
NAFLD	Activity	Score.	Negative	interaction	between	alcohol	and	BMI	
on	fibrosis	observed	.	Every	5	kg/m2	increased	BMI	conferred	2.2-
fold	increased	risk	of	fibrosis	in	non-alcoholics,	but	not	in	alcoholics.	
NAS	
	
Fibrosis	
Kwon	et	al,	
2014	[113]	
77	 Adults	>18	years	of	age	
with	presumed	NAFLD	
and	alcohol	consumption	
<40	g/week	were	enrolled	
Alcohol	consumption	<40	g/week	 On	multivariable	analysis,	increasing	age	(OR	1.07	[95%CI	1.01-1.14])	
associated	with	worse	liver	disease,	but	alcohol	consumption	≥24	
gram-years	associated	with	less	severe	disease	(OR	0.26	[95%CI	
0.07-0.97])	
	
OR:	Odds	Ratio;	95%CI:	95%	Confidence	interval	
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Table	5:	HCC	Development	in	setting	of	NAFLD	and	Alcohol	
	
Study	 Study	
Number	
Type	of	Study	 Count
ry	
Obesity/Fatty	liver	 Alcohol	consumption	
categories	
Key	reported	findings	
Lok	et	al,	2005	
[138]	
210	 Case-controlled	study	 USA	 Lean	(BMI	<25	kg/m2),	
overweight	(BMI	25.1–
30	kg/m2)	or	obese	
(BMI	>30	kg/m2	
None	(consumed	<100	
servings	of	alcohol	during	
his/her	lifetime,	<1500	
gram-years	(mild-to-
moderate)	or	1500	gram-
years	(heavy),		
6-fold	HCC	risk	increase	for	alcohol	(OR	5.7	[95%CI	2.4-
13.7]),	5-fold	for	tobacco	(OR	4.9	[2.2-10.6]),	4-fold	with	
obesity	(OR	4.3	[2.1–8.4])	
Loomba	et	al,	
2010	[133]	
2260	 Prospective	cohort	
study	from	the	Risk	
Evaluation	of	Viral	Load	
Elevation	and	
Associated	Liver	
Disease/Cancer–
Hepatitis	B	Virus	
(REVEAL–HBV)		
China	 Normal	BMI	(<23),	
overweight	(23–24.9),	
obese	(25–29.9),	
and	extremely	obese	
(≥30)	
<20	g/day	,	20-39	g/day,	40-
69	g/day,	and	≥70	g/day	
Risk	of	incident	HCC	increased	in	overweight	(HR	2.4	[95%	
CI	1.3-4.4]),	obese	(2.0	[1.1-3.7]),	and	extremely	obese	
(2.9	[1.0-8.0])	consumers	of	alcohol.	
Ascha	et	al,	
2010.	[221]	
510	 Retrospective	cohort	 USA	 Biopsy	 “Never,”	“social”	no	more	
than	two	alcoholic	drinks	
daily	or	three	to	six	drinks	
daily	on	weekends.	
“Significant”	more	than	two	
drinks	daily	or	more	than	six	
drinks	daily	on	weekends	for	
the	past	5	years.	“Formerly	
significant”	more	than	
“social	alcohol	intake”	
within	the	past	5	years.	
Age	and	alcohol	consumption	associated	with	HCC	risk	in	
NASH-cirrhosis.	Patients	with	regular	alcohol	
consumption	at	increased	HCC	risk	(HR	3.6).		
Loomba	at	el.	
2013,[94]		
23712	 Prospective	cohort	
study	
China	 Participants	were	
categorized	
into	normal	(<23),	
overweight	(23–24.9),	
obese	(25–29.9),	
and	extremely	obese	
(≥30)		
Alcohol	drinkers	were	
defined	as	those	who	had	
consumed	alcohol	at	least	4	
days	per	week	for	at	least	1	
year.	
Alcohol	use	and	obesity	increased	HCC	risk	in	unadjusted	
analyses	(HR	7.19	[95%CI	3.69-14.00])	and	multivariable-
adjusted	analyses	(age,	sex,	smoking,	serum	alanine	
aminotransferase,	serum	hepatitis	B	surface	antigen,	
anti-hepatitis	C	virus	antibody,	and	diabetes	mellitus)	(HR	
3.82	[1.94-7.52])	
Pais	et	al,	 110	 Retrospective	Cohort	 France	 Liver	Explant	review	 Alcoholic	cirrhosis	on	 Obesity/T2DM	in		ALD	transplant	recipients	increased	
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2015,	[222]	 explant	 HCC	risk	(OR	6.23	[95%	CI	2.47-15.76]	and	4.63	[1.87-
11.47]	respectively).	
Kawamura	et	
al,	2016	[132]		
9959	 Multicentre	
retrospective	analysis	
Japan	 Ultrasound		 <20	g/day,	20-39	g/day,	40-
69	g/day,	and	≥70	g/day	
Greater	alcohol	consumption	associated	with	HCC	
incidence:	0.06%	if	20-39	g/day	ethanol	(HR	1.54	[95%CI	
0.34-7.04]),	0.16%	if	40-69	g/day	(HR	3.49	[1.50-8.12]),	
]0.22%	if	≥70	g/day	(HR	10.58	[5.06-22.13]),	compared	to	
consumption	<20	g/day.	
OR:	Odds	Ratio;	HR:	Hazard	Ratio;	95%CI:	95%	Confidence	interval	
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